Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. METHODS: A comprehensive literature search of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xiao-Dan, Fu, Xue, He, Yuan-Qun, Li, Chun-Yan, Guo, Meng, Qiao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
6600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592351/
https://www.ncbi.nlm.nih.gov/pubmed/36281168
http://dx.doi.org/10.1097/MD.0000000000031183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592351/
https://www.ncbi.nlm.nih.gov/pubmed/36281168
http://dx.doi.org/10.1097/MD.0000000000031183

Ejemplares similares